Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and antitumor activity of a mutant type of interleukin 2.
Dehghan R, Beig Parikhani A, Zeinali S, Shokrgozar M, Amanzadeh A, Ajdary S, Ahangari Cohan R, Talebkhan Y, Behdani M. Dehghan R, et al. Among authors: talebkhan y. Sci Rep. 2022 Mar 30;12(1):5376. doi: 10.1038/s41598-022-09278-7. Sci Rep. 2022. PMID: 35354847 Free PMC article.
Improvement of Certolizumab Fab' properties by PASylation technology.
Mazaheri S, Talebkhan Y, Mahboudi F, Nematollahi L, Cohan RA, Mirabzadeh Ardakani E, Bayat E, Sabzalinejad M, Sardari S, Torkashvand F. Mazaheri S, et al. Among authors: talebkhan y. Sci Rep. 2020 Oct 28;10(1):18464. doi: 10.1038/s41598-020-74549-0. Sci Rep. 2020. PMID: 33116155 Free PMC article.
Extension of human GCSF serum half-life by the fusion of albumin binding domain.
Nikravesh FY, Shirkhani S, Bayat E, Talebkhan Y, Mirabzadeh E, Sabzalinejad M, Aliabadi HAM, Nematollahi L, Ardakani YH, Sardari S. Nikravesh FY, et al. Among authors: talebkhan y. Sci Rep. 2022 Jan 13;12(1):667. doi: 10.1038/s41598-021-04560-6. Sci Rep. 2022. PMID: 35027593 Free PMC article.
Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach.
Beig Parikhani A, Bagherzadeh K, Dehghan R, Biglari A, Shokrgozar MA, Riazi Rad F, Zeinali S, Talebkhan Y, Ajdary S, Ahangari Cohan R, Behdani M. Beig Parikhani A, et al. Among authors: talebkhan y. PLoS One. 2022 Feb 25;17(2):e0264353. doi: 10.1371/journal.pone.0264353. eCollection 2022. PLoS One. 2022. PMID: 35213635 Free PMC article.
Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate.
Oghalaie A, Mahboudi F, Rahimi-Jamnani F, Piri-Gavgani S, Kazemi-Lomedasht F, Hassanzadeh Eskafi A, Shahbazzadeh D, Adeli A, Talebkhan Y, Behdani M. Oghalaie A, et al. Among authors: talebkhan y. Iran J Basic Med Sci. 2022 Mar;25(3):313-319. doi: 10.22038/IJBMS.2022.62522.13834. Iran J Basic Med Sci. 2022. PMID: 35656179 Free PMC article.
Characterization of a novel mCH3 conjugated anti-PcrV scFv molecule.
Komijani S, Bayat E, Rismani E, Hosseini S, Moazzami R, Nematollahi L, Sardari S, Talebkhan Y, Davami F, Barkhordari F, Hosseini F, Jahandar H. Komijani S, et al. Among authors: talebkhan y. Sci Rep. 2021 Mar 30;11(1):7154. doi: 10.1038/s41598-021-86491-w. Sci Rep. 2021. PMID: 33785781 Free PMC article.
Recombinant anti-human epidermal growth factor receptor type 2 single-chain variable fragment-alpha-luffin fusion protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research.
Damough S, Bayat E, Oghabi Bakhshaiesh T, Barkhordari F, Esmaeili R, Nematollahi L, Talebkhan Y. Damough S, et al. Among authors: talebkhan y. Ann Med Surg (Lond). 2023 Jul 27;85(9):4348-4354. doi: 10.1097/MS9.0000000000000731. eCollection 2023 Sep. Ann Med Surg (Lond). 2023. PMID: 37663730 Free PMC article.
35 results